Introduction
The lysosomal enzyme arylsulfatase A (ASA; E.C.3.1.6.8.) catalyzes the desulfation of cerebroside 3-sulfate (sulfatide), an acidic sphingolipid mainly present in myelin sheaths. 1 The essential function of ASA in the sulfatide catabolism is reflected by the lysosomal storage disease metachromatic leukodystrophy (MLD). Deficiency of ASA causes the accumulation and massive intralysosomal deposition of this sphingolipid. The disease is further characterized by a progressive and widespread loss of myelinating cells leading to severe dysfunctions in the nervous system. In the most severe late infantile form of MLD, the first clinical signs usually appear before the third year of life and a rapidly progressing demyelination results in death usually before 9 years of age. To date, there is no effective treatment.
A mouse model for MLD has been generated via targeted disruption of the murine ASA gene. stages in the disease progression of MLD. 2, 3 Analyses of these mice lent new insights into the disease pathogenesis which were compromised in humans due to the lack of appropriate premortem tissue material. Thus, the view that the sulfatide storage in oligodendroglial and Schwann cells alone accounts for the complex pathogenic disease process seems to be oversimplified. ASA deficiency was also found to have a major impact on other cell types like astrocytes, microglial cells and subpopulations of neuronal cells, some of which show cellular malformations and dysfunctions even in the absence of histochemically detectable sulfatide storage. 2 In particular, ASA-deficient mice display a reduced diameter and cross-sectional area of central and peripheral nervous system axons. 2 The deficient mice show various progressive cerebellar deficits and a decline in brain stem auditory-evoked potentials between the age of 3 and 9 months. 4 This is due to a loss of ganglion cells in the acoustic ganglion of ASA-deficient mice. 5 Cell culture experiments indicate that the metabolic defect of cells deficient for an individual soluble lysosomal enzyme can be cross-corrected by exogenous application of this enzyme. 6 Cross-correction is a consequence of mannose 6-phosphate receptor-mediated internalization of external lysosomal enzymes into the lysosomal compartment and subsequent hydrolysis of the intralysosomally accumulated enzyme substrate. Except for some tumor-derived cell lines mannose 6-phosphate receptors have been detected in all cell types including neurons, astrocytes and oligodendrocytes, and mannose 6-phosphate-dependent endocytosis of lysosomal enzymes has been demonstrated for both glial and neuronal cells. 7, 8 The metabolic cross-correction of cultured cells and the ubiquituous expression of mannose 6-phosphate receptors favored efforts to establish clinically applicable methods for efficient substitution of the missing enzyme in patients. Repetitive intravenous injection of the deficient enzyme was found to be of therapeutic benefit only in some lysosomal storage diseases without central nervous system (CNS) involvement. 6 The explanation was, that the blood-brain barrier prevents the uptake of lysosomal enzymes from the blood stream into the brain parenchyma.
For lysosomal storage diseases with CNS pathology, bone marrow transplantation (BMT) has been suggested to be of potential therapeutic benefit. In the present view, the transmission of enzymatic activity to the CNS is based on bone marrow-derived cells of the monocyte/macrophage/microglial cell lineage that can repopulate the CNS and thus provide an intracerebral source of the missing enzyme. 9, 10 Allogeneic BMT using bone marrow from healthy donors has been applied to a number of MLD patients. However, due to the lack of appropriate controls and the variability of the disease phenotype even within families the therapeutic efficacy of BMT remains to be elucidated. It seems, however, that such an approach does not have the potential to halt disease progression. 11, 12 So far, only one case report has indicated a delay of the disease process. 13 In an attempt to assess the potential of BMT therapy more precisely, we performed BMT in ASA knockout mice. To increase ASA expression we used bone marrow that was transduced with a retroviral vector mediating overexpression of human ASA (hASA). As previously reported, transplantation of transduced bone marrow led to long-term reconstitution of transplanted animals and about 50% of reconstituted mice developed continuously high serum levels of hASA, declining from approximately 400 ng/ml to 150 ng/ml within 12 months following transplantation.
14 This group was killed 1 year after transplantation and analyzed for ASA levels in various organs.
14 Visceral organs showed normal and partially supranormal ASA activities whereas up to 33% of normal ASA activity was found in the brain. This value exceeds the enzyme activity levels which are sufficient to prevent the manifestation of MLD. 15, 16 The enzyme levels in serum correlated with the amount of enzyme found in the kidney and liver, suggesting that endocytosis determines the amount of ASA delivered to these tissues. There was no correlation of serum ASA levels with the amount of enzyme found in the brain, which demonstrated that delivery to the brain is not due to endocytosis, but possibly due to bone marrow-derived cells migrating into the brain, which depending on the proviral integration site may express more or less ASA after microglial differentiation.
In this study, we have analyzed the long-term therapeutic outcome of bone marrow stem cell gene transfer. We analyzed those mice expressing high amounts of ASA from the retrovirally transduced bone marrow for a period of 12 months following transplantation. The phenotype of ASA-deficient mice is well-characterized and a number of histological, biochemical and behavioral parameters allows the determination of putative therapeutic effects.
Results

Biochemical analysis of lipid levels
Sulfatide and galactocerebroside were quantified in lipid extracts of the liver, kidney and brain of 9-to 12.-monthold mice (Figure 1 ). When the sulfatide levels were normalized for protein levels, a significant reduction of sulfatide was detectable in liver (Figure 1a ), but not in kidney ( Figure 1b ) and forebrain ( Figure 1c ) (Student's t test; P Ͻ 0.025) of mice treated by gene therapy.
In MLD a decline in the ratio of sulfatide and galactocerebroside is a more sensitive measure for the metabolic defect than the sulfatide level per se. 1 We therefore com- Figure 1d ). In 2.-month-old wild-type control mice this ratio was around 2 and increased to 2.5 1 year after birth. In untreated ASA-deficient mice, the ratio was initially comparable to that of wild-type mice, but then decreased continuously to values around 1 in 1-year-old animals. One-year-old mock-treated mice showed a mean value of 1.2. However, the lipid ratios of age-matched treated mutants consistently exceeded those of the mock-treated mutants and reached a mean of 1.6. Thus, the galactocerebroside/sulfatide ratio indicates a therapymediated improvement of the sulfatide catabolism in the CNS. The levels of phospholipids or cholesterol did not display any differences between the four group of mice (not shown).
Histochemical analysis of sulfatide storage
Liver, kidney and brain of treated, mock-treated, untreated ASA knockout and untreated wild-type mice were examined histochemically for sulfatide storage by incubation with alcian blue at an age of 10 to 11 months. Untreated and mock-treated ASA-deficient mice showed a pattern of storage granules identical to that of 129/Ola x B6 outbred mice which was described previously.
2,3
Thus, storage was found in 40-100% of the bile duct profiles of liver sections obtained from mock-treated mice (n = 7) (Table 1) . Consistently, a large number of granules was readily detectable in all epithelial cells of affected bile ducts (Figure 2a ). Compared with these controls, storage was markedly reduced in nine of 13 age-matched mice treated by gene therapy. This reduction was indicated by a decrease in the proportion of bile duct profiles affected by storage and/or a reduced number of storing cells per duct profile as well as storage granules per cell (Table 1 ). In one recipient (shown in Figure 2b ) the liver was completely devoid of storage.
To compare the extent of storage reduction in liver with the corresponding hASA level we determined hASA by a catalytic activity assay utilizing the artificial substrate p-nitrocatechol sulfate and by ELISA. 14, 17 The activity assay is compromised by high background activities of unspecific sulfatases so that the hASA activity has to be calculated by subtraction of the mean sulfatase background activity (determined in livers of mocktreated, ASA-deficient mice) from the compound sulfatase activity measured (not shown). Division of the calculated data by corresponding ELISA data indicated a specific activity of hASA around 45 mU/g on average (see below). This value is close to the normal specific activity of gene-encoded hASA in human tissues and cell lines (40 mU/g). 14, 17 Since the ELISA is specific for hASA and thus superior to the activity assay in the precise evaluation of minor differences in hASA expression levels it was used for all other analyses.
In the liver, a dependency of the extent of storage reduction on the hASA level was noticeable (Table 1 , Figure 2g) . Thus, the three animals with ASA levels of 18 ng/mg or below did not show a decline of storage material, while a reduction was evident in nine of 10 animals with levels above this threshold. Among these nine mice levels from 19 to 40 ng/mg yielded a less prominent decline as judged from the number of storing cells per affected bile duct and the number of storage granules per Gene Therapy cell. The only exception from this correlation is a liver (from mouse No. 921) with an ASA level of 126 ng/mg in which, despite the high concentration, no decline of storage was detectable.
To determine whether the hASA polypeptide expressed in this particular mouse had a reduced catalytic activity we measured the hASA activity of liver extracts of mouse No. 921 and eight other recipients by p-nitrocatechol sulfate assays. The calculated specific activity of retrovirally expressed hASA was 45.7 ± 19.2 mU/g (mean ± S.D, n = 8) in the control group. Compared with the controls the hASA polypeptide of mouse No. 921 displayed a reduced specific activity of 12.1 mU/g (not shown).
In kidneys of mock-treated mice sulfatide storage was regularly visible in the epithelia of the distal nephron ( Figure 2c ). Among the mice treated by gene therapy, histological improvement was prominent in only one of 12 recipients analyzed (shown in Figure 2d ). The ASA level in the kidney of this animal was 87 ng/mg tissue protein.
The other 11 kidneys showed levels below 27 ng/mg ASA and no positive effect on the histopathology was evident ( Figure 2g ).
Comparative examination of corresponding brain regions of seven mock-treated and 12 treated mice (such as the basal cerebral peduncle shown in Figure 2e and f) did not reveal any differences in the number, distribution or histological appearance of storage granules between these groups of animals. In the CNS of treated mice up to 10 (brainstem, forebrain) and 14 ng/mg ASA (cerebellum) were detected ( Figure 2g and Ref. 14) .
Acoustic ganglion and auditory function
In mice ASA deficiency causes a progressive loss of acoustic ganglion cells and a concomitant hearing loss. 5 To monitor a potential therapeutic effect of stem cell gene therapy on this process, we determined the density of neuronal cells within the acoustic ganglion by histological examination as described previously. The ganglion of ASA-deficient and wild-type mice harbors equal numbers of neurons per evaluated area at birth (Figure 3a) . In wild-type control mice, the density of neurons declines only slightly during adulthood. In untreated and mocktreated ASA-deficient mice, however, the neuronal cells rapidly disappear resulting in a reduction by 90% of cells 12 months after birth. No significant difference was detectable between these two groups and treated mice. Thus, gene transfer did not delay the loss of ganglion cells.
Recording of auditory-evoked potentials in the brainstem indicated a complete lack of potentials in a mocktreated and a treated mutant 1 year after birth. This confirms the conclusion of the histological analysis that treatment does not result in an improvement of the auditory function (Figure 3b) .
Determination of axon cross-sectional areas
Previous histological examination of 1-year-old ASAdeficient mice revealed a reduction of the axon cross-sectional area of myelinated fibers in the optic nerve, the corpus callosum and the sciatic nerve. 2 To determine a possible effect of gene therapy on neurons we determined cross-sectional areas of axons in the saphenus nerve, the sciatic nerve and the optic nerve around 12 months after birth (Figure 4) . For all nerves the cross- Table 1 To evaluate the effect of gene therapy, treated mice were compared with mocktreated controls. For the saphenus and sciatic nerve, therapy increased the reduced cross-sectional areas significantly (P Ͻ 0.01) and the medians attained values slightly above wild-type controls (Figure 4a and b , respectively). In contrast to the peripheral nervous system no therapy-mediated corrective response was detectable for the optic nerve in the CNS. Here, the axon cross-sectional areas of treated and mock-treated mice were almost identical (Figure 4c .
Figure 2 Sulfatide storage in (a, b) liver, (c, d) kidney and (e, f) brain (basal cerebral peduncle) of mock-treated (a, c, e) and treated (b, d, f) mice 10-11 months of age. Intralysosomal sulfatide granules are stained with alcian blue. A decline of storage is visible in liver (the arrow in b indicates the bile duct epithelium) and kidney, but not in brain. (g) Correlation between histologically detectable reduction of storage and the tissue level of hASA (for liver also see
Behavioral tests
Mice were tested at an age of 12-13 months. Analysis of the general motor activity revealed hyperactivity in mock-treated ASA-deficient mice (Figure 5a and b) . Thus, the cage activity was higher than in wild-type control mice (Figure 5a ) and also the frequency of transitions between the illuminated and the dark compartment in the dark light transition box was increased (Figure 5b) . Since an increased motor activity had not been described for ASA-deficient mice previously, we also included untreated ASA knockout mice in these two behavioral tests. For the cage activity one-way ANOVA shows a significant difference in the mean activity between the three Gene Therapy groups of deficient animals and wild-type mice (F 3.55 = 11.1, P Ͻ 0.001). Multiple comparison (Dunnett's test) demonstrates significantly higher activity in all three deficient groups compared with wild-type controls (P Ͻ 0.05). Compared with untreated animals the mean activity of treated mice was significantly reduced by roughly 25% (P Ͻ 0.05). However, no significant difference was noted when treated animals were compared with mock-treated animals. For the transition activity no significant difference between the three groups of ASAdeficient mice was observed (Figure 5b ). The evaluation of the neuromotor coordination capabilities by rotarod experiments indicated reduced performance in ASA knockout mice when compared with wild-type controls. 2 To determine the performance of treated mice, we used two independent rotarod experiments.
In the first experiment, mice performed four trials with 24 h intervals on a constant speed (6 r.p.m.) rotarod apparatus ( Figure 5c ). All wild-type controls had the ability to stay on the rod for at least 2 min from the second trials onwards, whereas in mock-treated animals significantly lower proportions of animals were able to balance on the rod during trials 2-4 (Fisher exact test; P Ͻ 0.01 on trials 2-4). Treated animals were slightly but not significantly better than mock-treated animals on all trials.
In the second experiment, mice performed four consecutive trials on an accelerating rotarod (Figure 5d) . Again, performance of treated mice was consistently but not significantly better than that of mock-treated animals. However, taken as a whole, the wild-type control group performed 76 trials of which 16 (21%) were successful (ie animals stayed on the rod for 5 min), whereas the mocktreated deficient group performed 40 trials of which only one (2.5%) was successful (chi-square test; P = 0.016 versus control). In contrast, the treated group performed 64 trials of which eight (12.5%) were successful (chi-square test; P = 0.27 versus control), which made their performance more similar to that of the control group. This slightly better performance of treated ASA-deficient mice in both rotarod experiments might indicate marginally improved neuromotor abilities in this group compared with mock-treated ASA-deficient animals.
Immune response
The potential of stem cell gene therapy can be limited by an immune response towards the transgene product. 18 To test a putative immune response against hASA, serum of long-term reconstituted recipients (age 9 to 12 months) was isolated and ␣-hASA antibodies were determined. Despite the long-term expression of hASA in treated mice in none of the animals were antibodies against the transgene product detectable. In contrast, wild-type mice injected intraperitoneally with recombinant hASA as a control developed ␣-hASA antibodies capable of precipitating hASA in vitro ( Figure 6 ). Thus, MSCV-asa-mediated expression of hASA in mice appears not to be compromised by a humoral immune response against the transgene product.
Discussion
Transfer of the human ASA cDNA into 5-6-week-old ASA-deficient mice by transplantation of BMCs transduced with MSCV-asa resulted in the continuous expression of hASA as detected by monitoring of hASA serum levels.
14 Transmission of hASA activity into visceral tissues on average leads to enzyme levels between 100 (kidney) and 800% (spleen, bone marrow) of wildtype levels. Transmission to the CNS was less effective, such that up to 33% of normal enzyme activity was achieved ( Figure 2g and Ref. 14) . Semiquantitative PCR revealed that 0.1 to 0.3% of brain cells were of donor type 1 year after transplantation.
14 This study has evaluated the possible therapeutic effects mediated by this stem cell gene transfer approach. For the determination of the therapeutic outcome, treated mice which continuously expressed hASA were compared about 1 year after BMT with mock-treated mice, ie ASA knockout mice which were transplanted with nontransduced bone marrow from deficient donors and had undergone all processes of BMT, in particular, lethal irradiation.
Biochemical determination of the sulfatide content in organs revealed that treatment reduces the mean lipid storage in the liver to about 70% of the level found in mock-treated animals, but no effect was seen in kidney and brain (Figure 1a, b, c) . In brain tissue of MLD patients sulfatide elevation is accompanied by a decrease in galactocerebroside. Therefore, the ratio of galactocerebroside to sulfatide is a sensitive indicator for abnormalities of lipid metabolism. The ratio of the two lipids shows a significant increase upon treatment. The galactocerebroside/sulfatide ratio of brains of wild-type mice at the age of 1 year is about 2.5, in mock-treated animals 1.2 and 1.6 in treated mice (Figure 1d) .
In addition to TLC we also evaluated sulfatide storage histochemically by alcian blue staining. Histochemical analysis of treated mice killed 10-11 months after BMT revealed a reduction of lysosomal lipid storage in liver in nine of 13 recipients (Table 1, Figure 2a and b) . Strikingly, except for mouse No. 921, an ASA level above 18 ng per mg tissue protein was paralleled by a decline of intralysosomal storage while in recipients showing tissue levels below this threshold the distribution, number and size of storage granules was indistinguishable from that of agematched mock-treated ASA-deficient mice. The observed amelioration of the histopathology indicates that functional hASA reached the lysosomal compartment of recipient cells after secretion by donor-type cells.
The failure of histological improvement in mouse No. 921 can be explained by a reduced activity of the hASA polypeptide in this particular animal. Compared with livers of control animals which display a normal specific hASA activity of 45 mU/g the specific activity was diminished by roughly 75% to 12.1 mU/g (not shown). The reduced activity suggests a mutation in the hASA
Figure 4 Cross-sectional areas of axons of myelinated fibers in the saphenus nerve (a), the sciatic nerve (b) and the optic nerve (c) in the three indicated groups of mice at an age of 11.5 to 12.5 months. The box plots show the 25% and 75% percentiles (boxes), the median (horizontal line) and the overall distribution of values (vertical lines). Due to the heterogeneity of axon calibers in the optic nerve a logarithmic scale was used in panel c. Per group, four to 11 mice were examined and the total number of analyzed axons is indicated.
cDNA of the integrated provirus that interferes with the normal catalytic function of the enzyme. This notion is supported by activity data obtained for bone marrow of mouse No. 921 where a reduced specific activity of 18.0 mU/g was determined (not shown).
The histochemical evaluation also revealed a reduction of lysosomal storage for kidney, but this response was restricted to one recipient (Figure 2c and d) . This single animal showed a more than three-fold higher level of ASA in kidney than other recipients (Figure 2g) . The available set of data allows the estimation that the minimal enzyme concentration mediating histological improvement of the kidney is above 27 ng/mg ASA.
This level is comparable to values found in the liver of treated animals (18 ng/mg ASA, see above) in which sulfatide reduction was found. This demonstrates a dependency of the therapeutic efficacy on the concentration of the substituted enzyme and suggests a similar threshold value for liver and kidney. The existence of a comparable corrective threshold of ASA activity for brain could explain the failure of treatment with regard to a reduction of sulfatide storage in the CNS (Figure 2e and f). In the brain which is less readily accessible to bone marrow-derived cells than visceral tissues, a maximum of approximately 10 ng/mg ASA was reached and this level is around two-to three-fold below the minimum level required for correction in liver and kidney ( Figure  2g ). 14 The endogenous ASA activity of wild-type control mice is about 1.0 mU/mg tissue protein for liver, 0.8 mU/mg for kidney and 1.8 mU/mg for forebrain. 14 The specific activity of MSCV-asa-encoded hASA is around 40 mU hASA/g hASA in cultured mouse cells and in
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livers of treated animals (see above). 17 Thus, 20 ng ASA/mg tissue protein resemble roughly 1.0 mU/mg ASA or 100% of the normal activity. Therefore it can be concluded, that ASA levels at least in the range of the normal ASA activity are required to achieve improvement of the histopathology.
The requirement of such high levels of ASA is surprising. In humans, a residual ASA activity of 5-10% of normal prevents the manifestation of MLD, and thus it was supposed that similar levels might be therapeutically effective in mice. 15, 16 The finding that unexpectedly high amounts of ASA have to be substituted for correction of sulfatide storage may be due to several reasons. Low amounts of residual enzyme activity are sufficient to prevent storage in normal equilibrium conditions, in which sulfatide does not accumulate. In contrast, the degradation of stored aggregated sulfatide may require much higher amounts of enzyme. However, in other lipid storage disorders such as Gaucher's disease low amounts of substituted enzyme are sufficient to reverse glucocerebroside storage, and upon BMT in mice with Sandhoff's disease the amount of gangliosides in the liver was substantially reduced although only 40% of normal ␤-hexosaminidase activity was reached in this organ. 19, 20 Thus, compared with other lipid storage diseases stored sulfatide or ASA may have particular properties requiring comparatively large amounts of enzyme for amelioration of storage. The lysosomal deposition of sulfatide is paralleled by an enrichment of this sphingolipid in the cytoplasmic membrane and such membranes display physicochemical characteristics distinct from normal membranes. [21] [22] [23] Thus, a mass- ive accumulation of the negatively charged sulfatide in membranes might reduce the efficiency of mannose 6-phosphate receptor-mediated endocytosis and/or lysosomal targeting of exogenous ASA. This would prevent an efficient supply of lysosomes with the substituted ASA. The timing of correction may also be essential. Transplanting newborn mice, in which the blood-brain barrier is still open, may yield higher activities and reduction of storage in the brain. In addition, cells which died due to sulfatide storage may be cleared at the tissue-specific pace being faster in the liver than in the brain.
Finally, one may raise the question about the effectiveness of human ASA correcting the metabolic defect in mice. However, we have performed extensive control experiments to verify the structural and functional integrity of the MSCV-asa-encoded hASA polypeptide following expression in cultured mouse cells. 17 Thus, the spe- cific activity, secretion, intracellular sorting and half-life of the enzyme was normal and it corrected the metabolic defect of ASA-deficient mouse glial cells upon intracellular expression or endocytosis. Furthermore, hASA isolated from the brain of treated mice hydrolyzed sulfatide in an in vitro assay efficiently.
14 It is therefore unlikely that the need of high hASA concentrations is due to functional deficits of the retrovirally expressed enzyme in transplanted mice.
In ASA-deficient mice the diameter and cross-sectional area of axons and myelinated fibers in the central and peripheral nervous system is decreased. 2 Our data for the saphenus nerve, the sciatic nerve and the optic nerve confirm these previous results. Thus, in all nerves the crosssectional area of axons measured in mock-treated knockout mice are significantly reduced when compared with those of wild-type controls (Figure 4) . Importantly, gene therapy had the potential to improve this parameter to normal values and resulted in a significant increase of cross-sectional areas in the peripheral nervous system (saphenus nerve, sciatic nerve; Figure 4 a and b) . Treatment was, however, without effect in the CNS (optic nerve; Figure 4c ). The easiest explanation for the different response is the much higher level of ASA in the periphery compared with the CNS. Impaired motor coordination has been shown in aging ASA-deficient mice and related to the loss of cerebellar Purkinje cells in these animals. 2, 4 Peripheral nervous system defects may also contribute, at least partially, to the neuromotor impairments in ASA knockouts, and the observed therapy-related improvement of peripheral axon diameters could possibly attenuate some of these impairments. Our behavioral observations indeed suggest marginal improvement of neurological symptoms in ASA-deficient mice. Some of the data seemed to indicate improvement of rotarod performance in treated, but not in mock-treated knockout mice (Figure 5c and d) . Also, even though treated mice still displayed hyperactivity as indicated by both cage and dark-light transition measures, their cage activity was significantly reduced compared with untreated ASA-deficient controls (Figure 5a) . No difference was found, however, between treated and mock-treated animals in cage activity, and exploratory activity was similar in all three groups of knockout mice (Figure 5b) . Thus, although neuromotor deficits definitely persist in treated ASA-deficient mice, some marginal improvement of their symptoms can be demonstrated.
In summary, stem cell gene transfer led to substantial amounts of ASA activity in the CNS of ASA-deficient mice, but had only minor corrective effects on the neuropathology. Thus, no halt or delay of the loss of neurons as judged from the acoustic ganglion analysis (Figure 3 ) was detectable. However, increased fiber diameters, improvements of the ratio of galactocerebroside to sulfatide in brain and slight improvements in some behavioral studies indicate a positive effect of the therapy in the nervous system. This resembles results of BMT transplantation studies in MLD patients. These have indicated that in the severe late infantile forms of the disease BMT has no beneficial effect, but that transplantations in presymptomatic late onset patients seem to delay disease progression in some cases. 13 However, in comparison to conventional BMT in humans it is unexpected that the higher ASA amounts provided by the ASA gene transfer protocol in mice did not yield better therapeutic effects. A number of reasons which have to be examined in the future may account for this, but one should realize that at this stage the data presented do not prove that conventional BMT in humans would be insufficient.
Materials and methods
Mice and gene transfer Inbred mice (129/Ola) were used throughout this study. ASA knockout mice were generated, bred and transplanted as described. 2, 14 Briefly, male donors were injected with 5-fluorouracil and bone marrow cells (BMC) were isolated by flushing femurs and tibias 2-3 days later. BMC were precultured in the presence of stem cell factor, interleukin-3 and interleukin-6 for 2 days and then cocultured with amphotropic GP+AM12 producer cells for MSCV-asa for 2 days in the presence of cytokines and polybrene. Five-to 6-week-old female mice were submitted to a total body irradiation of 9.5 Gy from a [
137 Cs] source and transplanted with the coculture-transduced BMC by intravenous injection. The ASA expression of treated mice was monitored by determining serum levels of hASA several times a month using an ELISA which is specific for the hASA polypeptide.
14 Only recipients continously expressing ASA in serum were used in this study. For the generation of mock-treated mice, precultured BMC were cultured for 2 days in the absence of producer cells and transplanted into lethally irradiated female siblings of treated mice.
Putative therapeutic effects of stem cell gene transfer were evaluated by comparative analysis of three groups of age-matched female mice: (1) untreated wild-type mice, (2) mock-treated ASA deficient mice (ie animals which were transplanted with nontransduced ASAdeficient BMCs) and (3) treated ASA-deficient mice (ie Gene Therapy animals which received retrovirally transduced bone marrow stem cells). For some analyses age-matched untreated ASA knockout mice were also included. Unless otherwise stated, biochemical, histological and behavioral examinations were performed at an age of 9 to 13 months.
Histological investigations
For the analysis of ASA expression and lysosomal storage deposits, mice (wild-type, ASA-deficient, ASAdeficient/treated and ASA-deficient/mock-treated animals) were transcardially perfused with 50 ml PBS and dissected tissue samples were either fixed by immersion in modified Bouin's solution (diluted 1:4 with PBS) or frozen. For the biochemical determination of lipids and ASA concentrations frozen specimens were processed as described below. For the histochemical detection of stored sulfolipids, fixed tissue blocks were incubated for 2-3 weeks in 0.05% (w/v) alcian blue in 0.025 m Na-acetate buffer, pH 5.7, containing 0.3 m MgCl 2 and 1% (w/v) paraformaldehyde. The specific conditions warrant specific staining of sulfated macromolecules. 24 Other mice were fixed by transcardiac transfusion with either 6% glutaraldehyde or modified Bouin's solution and specimens were embedded in araldite and paraffin, respectively, using standard protocols.
For the quantitative analysis of axon and myelin sheath diameters, semithin sections of glutaraldehyde-fixed material were cut at 1 m and myelin sheaths were stained with p-phenylenediamine. Images were digitized at a resolution of 1024 × 768 pixels using a primary magnification of 63× and a 2.5× projection lens and transferred to an image analysis software (OPTIMAS 6.5 and Analysis 2.3).
The density of neuronal cells in the acoustic ganglion was determined as described. 5 Determination of hASA and ␣-hASA antibodies The concentration of hASA protein in tissues and serum was determined by ELISA using ␣-hASA antibodies as described.
14 The hASA activity in tissues was evaluated by enzymatic assays using p-nitrocatecholsulfate as a substrate.
14, 25 The presence of ␣-hASA antibodies in mouse serum was determined by an immunoprecipitation assay described previously. 26 Briefly, 30 l of a solution with 30 mU/ml recombinant human ASA was mixed with various dilutions of serum from transplanted mice. The samples were incubated at 4°C overnight and the next day 5 g of affinity purified rabbit anti-mouse IgG (Dianova, Hamburg, Germany) was added. One hour later immunglobulins were collected for 30 min by the addition of a suspension of Staphylococcus aureus. After centrifugation ASA activity was measured in the pellet and the supernatant. Preimmuneserum and serum of mice immunized intraperitoneally with recombinant ASA served as negative and positive controls, respectively.
Lipid analysis
The frozen tissues were mortared under liquid nitrogen. Approximately 100 mg of the homogenized tissue powder was taken for lipid extraction with chloroform:methanol:water (C/M/W 4:8:3, by volume). 27 Phase partition was performed in C/M/0.1 m KCl (10:5:2, by volume). The final lipid fraction was stored in C/M/W (60:30:4.5, by volume) and aliquots were taken for the determination of lipids. Sulfatide and galactocerebroside were quantified by densitometry after high performance TLC and orcinol visualization. 28 Behavioral tests and electrophysiology Animals were kept in small groups under standard animal housing conditions with 12/12 h dark-light schedule, rodent chow and water ad libitum and constant room temperature and humidity. Cage activity was recorded in solitary housed mice during dusk and dark phase of their activity. Animals were put in transparent mouse cages (20 × 25 cm 2 ), which were placed between three infrared photobeams. The number of beam crossings during the recording interval (16 h) was counted with a microprocessor counter and used as expression of mainly ambulatory cage activity. Exploratory activity was assessed in a dark-light transition box equipped with photoelectric beams and interruption counter. The box consisted of a small dark compartment (10 × 75 cm 2 ), a larger brightly illuminated compartment (30 × 75 cm 2 ) and a dividing wall with four small holes allowing transition between compartments. During the dark phase of their activity cycle, mice were placed in the box starting from the dark compartment and two photobeams parallel to the dividing wall were used to count the number of transitions during a 10-min interval. Finally, motor coordination and equilibrium were tested in the rotarod test. During two independent observations either a constant speed of 6 r.p.m. or an apparatus accelerating in 5 min from 4 to 40 r.p.m. was used. 2, 29 In both instances testing consisted of four trials during which the animals were placed on a rotating rod. The number of animals able to stay on the rod during a fixed interval (5 or 2 min, respectively) was compared between groups. Significance of differences between means was assessed using either one-way ANOVA and Dunnett's multiple comparison test or Student's t test. Differences between proportions were analyzed with Fisher's exact test or the chi-square test.
The recording of brain stem auditory-evoked potentials was performed as reported. 
